On July 10, 2025, Tonix Pharmaceuticals Holding Corp. reported new findings on its TNX-801 vaccine at the Vaccine Congress 2025, highlighting its ability to offer durable immunity with lower virulence compared to existing vaccines. The data showed its safety and efficacy in various animal models, suggesting potential for controlling mpox and smallpox.